Loading clinical trials...
Loading clinical trials...
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
8559073286Clinical.Trials@bms.comFirst line of the email MUST contain the NCT# and Site #.
CONTACT
Lead Sponsor
Celgene
NCT07571161 · Alzheimer Disease
NCT06847321 · Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
NCT06937229 · Alzheimer Disease, Agitation
NCT04579120 · Alzheimer Disease
NCT07633470 · Alzheimer Disease
Local Institution - 0046
Homewood, Alabama
University of Alabama - Huntsville Regional Medical Campus
Huntsville, Alabama
NoesisPharma
Phoenix, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions